Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126171471 | 12617147 | 1 | I | 20160726 | 20160803 | 20160803 | EXP | US-ASTRAZENECA-2016SE81360 | ASTRAZENECA | 0.00 | F | Y | 67.60000 | KG | 20160803 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126171471 | 12617147 | 1 | SS | METOPROLOL TARTRATE. | METOPROLOL TARTRATE | 1 | Oral | 0 | 50 | MG | BID | ||||||||
| 126171471 | 12617147 | 2 | PS | BRILINTA | TICAGRELOR | 1 | Oral | 22433 | 90 | MG | TABLET | Q12H | |||||||
| 126171471 | 12617147 | 3 | SS | BRILINTA | TICAGRELOR | 1 | Oral | 22433 | 90 | MG | TABLET | Q12H | |||||||
| 126171471 | 12617147 | 4 | SS | BRILINTA | TICAGRELOR | 1 | Oral | 22433 | 90 | MG | TABLET | Q12H | |||||||
| 126171471 | 12617147 | 5 | C | GLYBURIDE METFORMIN | 2 | Oral | 0 | ||||||||||||
| 126171471 | 12617147 | 6 | C | AMLODIPINE BESLATE | 2 | Oral | 0 | 5 | MG | QD | |||||||||
| 126171471 | 12617147 | 7 | C | RAMIPRIL. | RAMIPRIL | 1 | Oral | 0 | 5 | MG | QD | ||||||||
| 126171471 | 12617147 | 8 | C | ATORVASTATIN | ATORVASTATIN | 1 | Oral | 0 | 80 | MG | QD | ||||||||
| 126171471 | 12617147 | 9 | C | ATORVASTATIN | ATORVASTATIN | 1 | Oral | 0 | 80 | MG | QD | ||||||||
| 126171471 | 12617147 | 10 | C | LOSARTAN POTASSIUM. | LOSARTAN POTASSIUM | 1 | Oral | 0 | 100 | MG | QD | ||||||||
| 126171471 | 12617147 | 11 | C | LOSARTAN POTASSIUM. | LOSARTAN POTASSIUM | 1 | Oral | 0 | 100 | MG | QD | ||||||||
| 126171471 | 12617147 | 12 | C | ASPIRIN. | ASPIRIN | 1 | Oral | 0 | 81 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126171471 | 12617147 | 1 | Hypertension |
| 126171471 | 12617147 | 2 | Acute coronary syndrome |
| 126171471 | 12617147 | 3 | Myocardial infarction |
| 126171471 | 12617147 | 4 | Stent placement |
| 126171471 | 12617147 | 5 | Diabetes mellitus |
| 126171471 | 12617147 | 6 | Hypertension |
| 126171471 | 12617147 | 7 | Hypertension |
| 126171471 | 12617147 | 8 | Hypertension |
| 126171471 | 12617147 | 9 | Blood cholesterol abnormal |
| 126171471 | 12617147 | 10 | Hypertension |
| 126171471 | 12617147 | 11 | Blood cholesterol abnormal |
| 126171471 | 12617147 | 12 | Cardiac disorder |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126171471 | 12617147 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126171471 | 12617147 | Dyspnoea | |
| 126171471 | 12617147 | Myocardial infarction |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126171471 | 12617147 | 1 | 2010 | 0 | ||
| 126171471 | 12617147 | 2 | 20160627 | 0 | ||
| 126171471 | 12617147 | 3 | 20160627 | 0 | ||
| 126171471 | 12617147 | 4 | 20160627 | 0 | ||
| 126171471 | 12617147 | 5 | 2006 | 0 | ||
| 126171471 | 12617147 | 6 | 2010 | 0 | ||
| 126171471 | 12617147 | 7 | 2014 | 0 | ||
| 126171471 | 12617147 | 8 | 2010 | 0 | ||
| 126171471 | 12617147 | 9 | 2010 | 0 | ||
| 126171471 | 12617147 | 10 | 2014 | 0 | ||
| 126171471 | 12617147 | 11 | 2014 | 0 | ||
| 126171471 | 12617147 | 12 | 2014 | 0 |